|
Timothy T. Goodnow, Ph.D.
President & CEO
Dr. Goodnow joined the SMSI Board of Directors
in December 2010 and on March 1, 2011 became President
& CEO of SMSI. Dr. Goodnow was most recently with
Abbott Diabetes Care where he was the Vice President,
Technical Operations. Prior to that, he held positions
at TheraSense, Verax Biomedical, Dade Behring and Baxter
Healthcare. Dr. Goodnow has led the successful development
of a number of FDA approved glucose monitoring systems
and insulin pumps. He holds a Ph.D. and B.S. in Chemistry
from the University of Miami. top
Todd Whitehurst, MD
Vice President of Product Development
Prior to joining SMSI, Dr. Whitehurst
was the VP of R&D at Palyon Corp for 2 years, where
he led the effort to develop and produce a next-generation
implantable drug infusion pump for the treatment of
chronic pain and spasticity. He served as Director and
VP of Emerging Indications from 2002 to 2009 at Boston
Scientific Neuromodulation (formerly part of Advanced
Bionics Corporation), where he led the research, development,
and evaluation of new technologies for neuromodulation,
including the Bion microstimulator. Prior to that, he
worked for over a decade as an electrical engineer and
software engineer in the R&D departments of several
medical device companies, including Advanced Bionics
and SRI International. He holds an MD from UCSF, an
MS in Electrical Engineering and Computer Science (EECS)
from UC-Berkeley, and a BE in EECS from Vanderbilt University.
top
Arthur E. Colvin
Senior Scientist
Mr. Colvin has served as Senior
Scientist of SMSI since its inception in January 1997.
Mr. Colvin is the inventor of the Company's core technology,
and owner of the corresponding U.S. patent. Before founding
SMSI, Mr. Colvin founded and served as President of
Cerex, a private company that developed products for
the fermentation market and provided contract engineering
and manufacturing services. Prior to Cerex, Mr. Colvin
was a staff scientist and process development engineer
for Life Technologies, Inc., where he was involved in
new product development.
Mr. Colvin has developed or led
the development of more than 50 products for the biotechnology
and food industries. He has more than 30 issued and
pending patents. top
Steven J. Walters
Director of Operations
Mr. Walters has been Director of
Operations of SMSI since May 2001. He is responsible
for production and quality operations of the company,
including its commercially available oxygen sensor for
which his team has implemented a high volume production
process. Prior to joining SMSI, he was Director of Operations
for Dye Magnet Industries (DMI), a consumer product
company, where he helped commercialize a new product.
He also participated in the sale of the company to consumer
product giant Reckitt Benckiser. Before joining DMI,
Mr. Walters was President of Larox Inc., a Finnish owned
capital equipment manufacturer. He oversaw the growth
of this company for more than 15 years with expansions
in the USA, Canada and Mexico. top
M. James Barrett, Ph.D.
Founder
Dr. Barrett is Founder of Sensors
for Medicine and Science, Inc.® (SMSI®).
He is currently a General Partner with the venture capital
firm New
Enterprise Associates. In 1987, he founded Genetic
Therapy, Inc. (GTI) which was sold in August of 1995
to Swiss pharmaceutical giant Sandoz AG (now Novartis)
for $300 million. He continued to serve as GTI's CEO
and as a Director through June 1996. He founded SMSI
in 1997.
From 1982 to July of 1987, Dr. Barrett
served as President of Life Technologies, Inc. (now
part of Invitrogen)
and its predecessor, Bethesda Research Laboratories.
Prior to 1982, he was employed at SmithKline
Beecham Corporation for 13 years, where he held
a variety of positions, including President of its In
Vitro Diagnostics Division and President of SmithKline
Clinical Laboratories. Dr. Barrett has been a Director
of MedImmune,
Inc. since 1988. top
Copyright © 2011 Sensors for Medicine and Science, Inc.®
All rights reserved. Date of last update: 11/2/11.
Refer to Terms and Conditions
for use of this Web site.
|
